Circulating maternal placental growth factor responses to low-molecular-weight heparin in pregnant patients at risk of placental dysfunction
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Circulating maternal placental growth factor responses to low-molecular-weight heparin in pregnant patients at risk of placental dysfunction
Authors
Keywords
-
Journal
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-08-27
DOI
10.1016/j.ajog.2021.08.027
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Low-molecular-weight heparin for prevention of preeclampsia and other placenta-mediated complications: a systematic review and meta-analysis
- (2021) Monica Cruz-Lemini et al. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
- PlGF (Placental Growth Factor) Testing in Clinical Practice: Evidence From a Canadian Tertiary Maternity Referral Center
- (2021) Kelsey McLaughlin et al. HYPERTENSION
- Low molecular weight heparin promotes transcription and release of placental growth factor from endothelial cells
- (2020) Kelsey McLaughlin et al. AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
- Implementation of routine first trimester combined screening for pre‐eclampsia: a clinical effectiveness study
- (2020) GP Guy et al. BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY
- Prediction of Preeclampsia-Related Adverse Outcomes With the sFlt-1 (Soluble fms-Like Tyrosine Kinase 1)/PlGF (Placental Growth Factor)-Ratio in the Clinical Routine
- (2020) Lisa Antonia Dröge et al. HYPERTENSION
- Predictive Performance of PlGF (Placental Growth Factor) for Screening Preeclampsia in Asymptomatic Women
- (2019) Swati Agrawal et al. HYPERTENSION
- The Placental Basis of Fetal Growth Restriction
- (2019) Rebecca L. Zur et al. OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA
- A placenta clinic approach to the diagnosis and management of fetal growth restriction
- (2018) John C. Kingdom et al. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
- Effects of glycol-split low molecular weight heparin on placental, endothelial, and anti-inflammatory pathways relevant to preeclampsia†
- (2018) Jovian M Wat et al. BIOLOGY OF REPRODUCTION
- Low molecular weight heparin for the prevention of severe preeclampsia: where next?
- (2018) Kelsey McLaughlin et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Parental ethnicity and placental maternal vascular malperfusion pathology in healthy nulliparous women
- (2018) Melanie C. Audette et al. PLACENTA
- Performance of commercially available placental growth factor tests in women with suspected preterm pre-eclampsia; the COMPARE study
- (2018) F. P. McCarthy et al. ULTRASOUND IN OBSTETRICS & GYNECOLOGY
- Two-stage screening for preterm preeclampsia at 11-13 weeks’ gestation
- (2018) Alan Wright et al. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
- Prediction of Preeclampsia Using the Soluble fms-Like Tyrosine Kinase 1 to Placental Growth Factor RatioNovelty and Significance
- (2017) Ulla Sovio et al. HYPERTENSION
- Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia
- (2017) Daniel L. Rolnik et al. NEW ENGLAND JOURNAL OF MEDICINE
- Angiogenic Factor Profiles in Pregnant Women With a History of Early-Onset Severe Preeclampsia Receiving Low-Molecular-Weight Heparin Prophylaxis
- (2017) Edouard Lecarpentier et al. OBSTETRICS AND GYNECOLOGY
- Maternal Vascular Malperfusion and Adverse Perinatal Outcomes in Low-Risk Nulliparous Women
- (2017) Emily Wright et al. OBSTETRICS AND GYNECOLOGY
- The pregnancy outcome prediction (POP) study: Investigating the relationship between serial prenatal ultrasonography, biomarkers, placental phenotype and adverse pregnancy outcomes
- (2017) Francesca Gaccioli et al. PLACENTA
- Endothelial Dysfunction in Severe Preeclampsia is Mediated by Soluble Factors, Rather than Extracellular Vesicles
- (2017) Michelle O’Brien et al. Scientific Reports
- Maternal plasma angiogenic index-1 (placental growth factor/soluble vascular endothelial growth factor receptor-1) is a biomarker for the burden of placental lesions consistent with uteroplacental underperfusion: a longitudinal case-cohort study
- (2016) Steven J. Korzeniewski et al. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
- Sampling and Definitions of Placental Lesions: Amsterdam Placental Workshop Group Consensus Statement
- (2016) T. Yee Khong et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Low Molecular Weight Heparin Improves Endothelial Function in Pregnant Women at High Risk of PreeclampsiaNovelty and Significance
- (2016) Kelsey McLaughlin et al. HYPERTENSION
- Placental Growth Factor Administration Abolishes Placental Ischemia-Induced HypertensionNovelty and Significance
- (2016) Frank T. Spradley et al. HYPERTENSION
- Enoxaparin and Aspirin Compared With Aspirin Alone to Prevent Placenta-Mediated Pregnancy Complications
- (2016) Bassam Haddad et al. OBSTETRICS AND GYNECOLOGY
- Placental growth factor as a marker of fetal growth restriction caused by placental dysfunction
- (2016) Samantha J. Benton et al. PLACENTA
- Extending the scope of pooled analyses of individual patient biomarker data from heterogeneous laboratory platforms and cohorts using merging algorithms
- (2016) Órlaith Burke et al. Pregnancy Hypertension-An International Journal of Womens Cardiovascular Health
- Low molecular weight heparin therapy during pregnancy is associated with elevated circulatory levels of placental growth factor
- (2015) Y. Yinon et al. PLACENTA
- Angiogenic factors combined with clinical risk factors to predict preterm pre-eclampsia in nulliparous women: a predictive test accuracy study
- (2013) JE Myers et al. BJOG-AN INTERNATIONAL JOURNAL OF OBSTETRICS AND GYNAECOLOGY
- Diagnostic Accuracy of Placental Growth Factor in Women With Suspected Preeclampsia
- (2013) Lucy C. Chappell et al. CIRCULATION
- Urinary Excretion of C5b-9 in Severe Preeclampsia
- (2013) Richard M. Burwick et al. HYPERTENSION
- New Gestational Phase–Specific Cutoff Values for the Use of the Soluble fms-Like Tyrosine Kinase-1/Placental Growth Factor Ratio as a Diagnostic Test for Preeclampsia
- (2013) Stefan Verlohren et al. HYPERTENSION
- Maternal plasma concentrations of angiogenic/anti-angiogenic factors are of prognostic value in patients presenting to the obstetrical triage area with the suspicion of preeclampsia
- (2012) Tinnakorn Chaiworapongsa et al. Journal of Maternal-Fetal & Neonatal Medicine
- Can placental growth factor in maternal circulation identify fetuses with placental intrauterine growth restriction?
- (2011) Samantha J. Benton et al. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
- Is heparin a placental anticoagulant in high-risk pregnancies?
- (2011) J. C. P. Kingdom et al. BLOOD
- Unfractionated heparin for second trimester placental insufficiency: a pilot randomized trial
- (2011) J. C. P. KINGDOM et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- Heparin promotes soluble VEGF receptor expression in human placental villi to impair endothelial VEGF signaling
- (2011) S. DREWLO et al. JOURNAL OF THROMBOSIS AND HAEMOSTASIS
- A single rapid point-of-care placental growth factor determination as an aid in the diagnosis of preeclampsia
- (2011) Ulla B. Knudsen et al. Pregnancy Hypertension-An International Journal of Womens Cardiovascular Health
- Reference ranges for uterine artery mean pulsatility index at 11-41 weeks of gestation
- (2008) O. Gómez et al. ULTRASOUND IN OBSTETRICS & GYNECOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search